DOCSLIB.ORG

Interactions Adverse Effects, Treatment, Withdrawal, And

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Interactions Adverse Effects, Treatment, Withdrawal, And 1639 Nasal polyps. For discussion of the value of corticoster­ porphyrinogenic; it may be used as a drug of first choice Seretide; Thai.: Seretide; Seroflo; Turk.: Respiro; Seretide; UK: oids in the treatment of nasal polyps, including reference and no precautions are needed.1 Dymista; flutiform; Relvar Ellipta; Seretide; Ukr.: Seretide (CeperH,U); USA: Advair; Breo Ellipta; Dymista; Venez.: Seretide. to the use of fluticasone, see p. 1608.2. 1. The Drug Database for Acute Porphyria. Available at; http:l/www. drugs·porphyria.org (accessed 17/10/ll) Pharmacopoeial Prepara�ons Rhinitis. For a discussion of the management of rhinitis, BP 2014: Fluticasone Cream; Fluticasone Inhalation Powder, including the use of corticosteroids, see p. 612.1. Some Interactions 1 pre-dispensed; Fluticasone Inhalation Powder; Fluticasone Nasal further references to the use of fluticasone in rhinitis are The interactions of corticosteroids in general are described Drops; Fluticasone Nasal Spray; Fluticasone Ointment; Flutica­ given below. on p. 16!9.3. sone Pressurised Inhalation; 1. Wiseman LR, Benfield P. Intranasal fluticasone propionate: a reappraisal USP 36: Fluticasone Propionate Cream; Fluticasone Propionate of its pharmacology and clinical efficacy in the treatment of rhinitis. Inhalation Aerosol; Fluticasone Propionate Inhalation Powder; Drugs 1997; 53: 885-907. Pharmacokinetics Fluticasone Propionate Nasal Spray; Fluticasone Propionate 2. McCormack PL, Scott LJ.Fluticasone furoate: intranasal use in allergic Ointment. rhinitis. Drugs 2007; 67: 1905-15. For a brief outline of the pharmacokinetics of corticoster­ oids, see p. 1620.3. Fluticasone propionate is poorly absorbed from the Adverse Effects, Treatment, Withdrawal, and gastrointestinal tract and undergoes extensive first-pass Halcinonide (BAN. USAN, r/NN) @ Precautions metabolism; oral bioavailability is reported to be only about 1%. As for corticosteroids in general (see p. 1615.3, p. 1618.1, References. and p. 1618.3, respectively). Hypersensitivity reactions have I. Mackie AE, et al. Pharmacokinetics of intravenous fluticasone occurred with fluticasone. Eosinophilic conditions, includ­ 41: propionate in healthy subjects. Br 1 Clin Pharmacal 1996; 539-42. ing Churg-Strauss syndrome, have been reported rarely, in 2. van Boxte\ CJ, Sheffer AL, eds. The pharmacokinetics of fluticasone most cases after a tra_nsfer from oral corticosteroid therapy. propionate. Clin Pharmacokinet 2000; 39 {suppl): l-54. When applied topically, particularly to large areas, when 3. Daley-Yates PT, Baker RC. Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray the skin is broken, or under occlusive dressings, formulations. Br J Clin Pharmacal 2001; 51: 103-5. corticosteroids may be absorbed in sufficient amounts to 4. Allen A, et al. Absolute bioavailability of intranasal fluticasone furoate in cause systemic effects. Inhalation or nasal use of large healthy subjects. Clin Ther 2007; 29: 1415-20. amounts of fluticasone may produce systemic effects also (see below). Prepar (]lic:>n.�............ ..................................... USP 36: (Halcinonide). A white to off-white, odourless� Proprietary Preparations (details are given in Volume B) crystalline powder. Insoluble in water and in hexanes; Adrenal suppressian. Despite the fact that inhaled flutica­ Single�ingredient Preparations. Arg.: Alenys; Balivent; Crivanil; slightly soluble in alcohol and in ether; soluble in acetone sone is generally thought to lack systemic effects at thera­ Cutivate; Flixonase; Flixotide; Fluti-K; Fluticort; Inhalan; Lidil and in chloroform. peutic doses, a study in 25 healthy subjects1 indicated that Cort; Lirtodac; Proair; Rinisona; Austral.: Avamys; Flixonase fluticasone propionate as single inhaled doses of 250, 500, Allergy & Hayfever 24 Hour; Flixonase; Flixotide; Austria: Ava­ and 1000 micrograms did produce a reduction in plasma mys; Cutivate; Flixonase; Flixotide; Belg.: Avamys; Cutivate; Profile cortisol, indicating suppression of the hypothalamic-pitui­ Flixonase; Flixotide; Braz.: Avamys; Flixonase; Flixotide; Fluti­ Halcinonide is a corticosteroid used topically for its tary-adrenal axis to some degree. Others have also found can; Fluticaps; Flutivate; Plurair; Canad.: Avamys; Cutivate; glucocorticoid activity (p. 1597.1) in the treatment of evidence of adrenal suppression with fluticasone,2·5 parti­ Flonase; Flovent; Chile: Albeoler; Alenys; Avamys; Brexonase; various skin disorders. It is usually used as a 0.1% cream, cularly at high doses and in children, 6 and the effect may Brexoventt; Flixonase; Flixotide; Flucomix; Flusona; Fluticon; lotion, or ointment. · Flutivate; Nebulex; Raffonin; China: Cutivate be more marked with repeated than with single doses.4•6 8 (5�.J!J!l(); When applied topically, particularly to large areas, when Flixonase Flixotide Cz. : Alergonaset; Ali­ Several cases of adrenal crisis have been associated with (�!ifil!); (11i!if�)iJ); the skin is broken, or under occlusive dressings, sade; Avamys; Cutivate; Flixonaset; Flixotide; Nasofan; Denm.: high-dose inhaled fluticasone/·10 including at least one corticosteroids may be absorbed in sufficient amounts to Avamys; Cutivat; Flixonase; Flixotide; Flutide; Fin.: Flixonase; fatality 6 It has been recommended that children using cause systemic effects (p. 1615.3). The effects of topical inhaled fluticasone at doses above 400 micrograms daily Flixotide; Flutide; Nasofan; Fr.: Avamys; Flixonase; Flixotide; Flixovate; Ger.: Atemurt; Avamys; Fluticat; Flutide; Flutivate; corticosteroids on the skin are described on p. 1617.3. For should have adrenal function monitoring and a written Gr.: Alerxem; Avamys; Bocacort-S; Cortixide; Dennocort; Plica­ recommendations concerning the correct use of corticoster­ plan for emergency corticosteroid replacement therapy 6 zen; Flihaler; Flixocort; Flixoderm; Flixonase; Flixotide; Flixo­ oids on the skin, and a rough guide to the clinical potencies 1. Grahn€n A, et al. An assessment of the systemic activity of single doses of tide; Flucortis; Flutarzole; Fluticapen; Flutikrem; Flutinasal; of topical corticosteroids, see p. 1599.2. inhaled fluticasone propionate in healthy volunteers. Br J C!in Pharmacal 1994; 38: 521-5. Flutizal; Nasofan; Salenga; Ybecor; Hong Kong: Avamys; Cuti­ 2. Clark DJ, et al. Comparative systemic bioaL1ivity of inhaled budesonide vate; Dalman; Dermcasone; Flixonase; Flixotide; Lutisone; Preparations and fluticasone propionate in asthmatic children. Br J Clin Pharmacal Nasofan; Hung.: Avamys; Cutivate; Flixonase; Flixotide; Flutir­ ....... ............. 1996; 42: 264P. in; India: Flixonase; Floease; Flohale; Flomist; Flucasia; Fluster; ProprietaryPreparations (details are given in Volume B) 3. Rohatagi S, et al. Dynamic modeling of cortisol reduction after inhaled Flute; Fluticare; Fluticone; Flutiflo; Flutivate; Flutopic; Moli­ administration of flutkasone propionate. J Clin Pharmaco/ 1996; 36: 938-- derm; Nezaflo; Otrivin-C; Zoflut; Indon.: Avamys; Cutivatet; Single-ingredient Preparations. Braz. : Halog; Canad.: Halogt; 41. Flixonase; Flixotide; Medicort; Irl. : Avarnys; Flixonase; Flixo­ 4. Clark DJ, Lipworth BJ. Adrenal suppression with chronic dosing of China: Ha Le Te (�!@"*�); Cz.: Betaconont; Gr.: Ascochrom; fluticasone propionate compared with budesonide in adult asthmatic tide; Nasofan; Israel: Allegro; Avamys; Flixonase; Flixotide; Flu­ Hamiltoderm-D; Hong Kong: Halogt; India: Cortilate; Indon.: patients. Thorax 1997; 52: 55-8. titrim; Ital.: Avamys; Flixoderrn; Flixonase; Flixotide; Fluspiral; Halogt; Ital. : Halciderm; Mex. : Dermalog; Switz. : Betacortone; 5. Eid N, et a!. Decreased rnoming serum cortisol levels in children with Fluticrem; Nasofan; Ticavent; Jp n: Flonaset; Malaysia: Ava­ Turk.: Volog; USA: Halog; Venez. : Halog. asthma treated with inhaled fluticasone propionate. Pediatn"cs 2002; 109: mys; Cutivate; Flixonase; Flixotide; Flomist; Mex. : Avamys; 217-2 1. Canetit; Cutivate; Flixonase; Flixotide; Neth.: Avamys; Cortifil; 6. Paton J, et al. Adrenal responses to low dose synthetic ACTH Multi-ingredient Preparations. Braz. : Halog Capilar; Cz. : Betacor­ Cutivate; Flixonase; Flixotide; Fluticrem; Flutide; Norw.: Ava­ (Synacthen) in children receiving high dose inhaled fluticasone. Arch Dis ton Sf; Betacorton Ut; India: Cobederm-Ht; Cortilate-N; Corti­ Child 2006; 91: 808-13. mys; Flutide; Flutivate; NZ: Flixonase; Flixotide; Nasacleart; late-S; Halog-E; Orkid-S; Ital. : Halciderm Combi; Halciderm; 7. LOnnebo A, et al. An assessment of the systemic effects of single and Philipp. : Avamys; Cutivate; Flixotide; Nasoflo; Pol. : Alisade; Mex. : Dermalog-C; Switz. : Betacortone S; Betacortone; Turk. : repeated doses of inhaled lluticasone propionate and inhaled budeso­ Avamys; Cutivate; Fanipos; Flixonase; Flixotide; Port.: Asmatil; Betacorton; Venez.: Halcicomb; Halog. nide in healthy volunteers. Eur J Clin Pharmacal 1996; 49: 459-63. Asmo-Lavi; Avamys; Brisovent; Cutivate; Eusticlil; Flixotaide; AM 8. Wilson , et a!. Adrenal suppression with high doses of inhaled Flutaide; Rontilona; Ubizol; Rus.: Avamys (ABaMHc); Cutivate f!uticasone propionate and triamcinolone acetonide in healthy Pharmacopoeial Preparations (KyTHBeih); Flixonase (cl>nHKCOH3.3e); Flixotide (cl>JIHKCOTH.U); voluteers. Bur J Clin Pharmacol 1997; 53: 33-7. USP 36: Halcinonide Cream; Halcinonide Ointment; Halcinonide 9. Todd GRG, et al. Survey of adrenal crisis associated with inhaled Nazare! (Ha3aperr); S.Afr. : Avamys; Cutivate; Flixonase;
Load more

Recommended publications
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • PRODUCT MONOGRAPH MYLAN-CLOBETASOL SCALP APPLICATION (Clobetasol 17-Propionate 0.05% W/W in Aqueous-Alcohol Base) (60 Ml Bottles
    PRODUCT MONOGRAPH MYLAN-CLOBETASOL SCALP APPLICATION (Clobetasol 17-propionate 0.05% w/w in aqueous-alcohol base) (60 ml bottles) Topical Corticosteroid Mylan Pharmaceuticals ULC DATE OF PREPARATION: 85 Advance Road Etobicoke, June 5, 2009 Ontario M8Z 2S6 DATE OF REVISION: Control#: 129665 NAME OF DRUG MYLAN-CLOBETASOL SCALP APPLICATION (Clobetasol 17-propionate 0.05 %w/w) (60 mL bottles) THERAPEUTIC CLASSIFICATION Topical Corticosteroid ACTIONS AND CLINICAL PHARMACOLOGY MYLAN-CLOBETASOL SCALP APPLICATION (Clobetasol 17-propionate) is a very potent topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Pharmacokinetics In man, the extent of percutaneous absorption of topical corticosteroids, including clobetasol 17-propionate, is determined by many factors, including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressing. As with all topical corticosteroids, clobetasol 17-propionate can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. 2 Once absorbed through the skin, topical corticosteroids enter pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids, including clobetasol 17-propionate and its metabolites, are also excreted in the bile. Bioavailability The relative potency of corticosteroids is usually assayed by the vasoconstriction test which reflects the potency of the steroid molecule, its topical activity as well as its bioavailaility from the particular formulation. The vascoconstrictor response of MYLAN-CLOBETASOL SCALP APPLICATION was compared with Dermovate Scalp Application as well as a placebo in a randomised and double blind study involving twelve healthy subjects.
    [Show full text]
  • Efficacy and Safety of Halometasone Cream to Treat Chronic Generalized Eczema and the Effects of Halometasone Cream on Serum Cortisol Levels
    Hindawi BioMed Research International Volume 2017, Article ID 3265024, 7 pages https://doi.org/10.1155/2017/3265024 Clinical Study Efficacy and Safety of Halometasone Cream to Treat Chronic Generalized Eczema and the Effects of Halometasone Cream on Serum Cortisol Levels Yan Li, Wei Xu, and Linfeng Li Department of Dermatology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China Correspondence should be addressed to Wei Xu; [email protected] Received 19 August 2017; Accepted 19 October 2017; Published 9 November 2017 Academic Editor: Fabio Sonvico Copyright © 2017 Yan Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The aim of the study was to investigate the efficacy and safety ofhalometasone cream to treat chronic generalized eczema and the effects of halometasone cream on serum cortisol (COR) levels. Sixty consecutive outpatients diagnosed with chronic generalized eczema between January and April 2017 were included and divided into groups A, B, and C with a lesion area of 30%–40%, 41%–50%, and51%–60%,respectively.GroupsA,B,andCweretreatedwithhalometasonecreamwithadailydoseof15g,20g,and30gfor 7–14 days, respectively. Ten patients were randomly selected from each group for serum COR measurement at days 0, 7, and 14. On day 14, group B had significantly higher cure rate (47.1%)than groups A (17.9%)and C (13.3%) and significantly higher effectiveness rate (82.4%) than group C (40.0%) (all < 0.05). Serum COR levels were not affected in group A but were reduced significantly in groups B and C on days 7 and 14 (all < 0.05).
    [Show full text]
  • Wo 2008/127291 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 23 October 2008 (23.10.2008) WO 2008/127291 A2 (51) International Patent Classification: Jeffrey, J. [US/US]; 106 Glenview Drive, Los Alamos, GOlN 33/53 (2006.01) GOlN 33/68 (2006.01) NM 87544 (US). HARRIS, Michael, N. [US/US]; 295 GOlN 21/76 (2006.01) GOlN 23/223 (2006.01) Kilby Avenue, Los Alamos, NM 87544 (US). BURRELL, Anthony, K. [NZ/US]; 2431 Canyon Glen, Los Alamos, (21) International Application Number: NM 87544 (US). PCT/US2007/021888 (74) Agents: COTTRELL, Bruce, H. et al.; Los Alamos (22) International Filing Date: 10 October 2007 (10.10.2007) National Laboratory, LGTP, MS A187, Los Alamos, NM 87545 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY,BZ, CA, CH, (30) Priority Data: CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, 60/850,594 10 October 2006 (10.10.2006) US ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicants (for all designated States except US): LOS LR, LS, LT, LU, LY,MA, MD, ME, MG, MK, MN, MW, ALAMOS NATIONAL SECURITY,LLC [US/US]; Los MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, Alamos National Laboratory, Lc/ip, Ms A187, Los Alamos, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, NM 87545 (US).
    [Show full text]
  • A Systematic Review of the Safety of Topical Therapies for Atopic Dermatitis J
    REVIEW ARTICLE DOI 10.1111/j.1365-2133.2006.07538.x A systematic review of the safety of topical therapies for atopic dermatitis J. Callen, S. Chamlin,* L.F. Eichenfield, C. Ellis,à M. Girardi,§ M. Goldfarb,à J. Hanifin,– P. Lee, D. Margolis,** A.S. Paller,* D. Piacquadio, W. Peterson, K. Kaulback,àà M. Fennerty– and B.U. Wintroub§§ Department of Dermatology, University of Louisville, Louisville, KY, U.S.A. *Department of Dermatology, Northwestern University’s Feinberg School of Medicine, Chicago, IL, U.S.A. Department of Dermatology, University of California San Diego, San Diego, CA, U.S.A. àDepartment of Dermatology, University of Michigan Medical School, Ann Arbor, MI, U.S.A. §Department of Dermatology, Yale University School of Medicine, New Haven, CT, U.S.A. –Department of Dermatology, Oregon Health and Science University, Portland, OR, U.S.A. **Departments of Dermatology and Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, PA, U.S.A. Department of Gastroenterology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, U.S.A. ààMedical Advisory Secretariat, Ministry of Health and Long Term Care, Toronto, ON, Canada §§Department of Dermatology, University of California San Francisco, 1701 Division Street, Room 338, San Francisco, CA 94143-0316, U.S.A. Summary Correspondence Background The safety of topical therapies for atopic dermatitis (AD), a common Bruce U. Wintroub. and morbid disease, has recently been the focus of increased scrutiny, adding E-mail: [email protected] confusion as how best to manage these patients. Objectives The objective of these systematic reviews was to determine the safety of Accepted for publication 9 June 2006 topical therapies for AD.
    [Show full text]
  • Atopic Dermatitis (1 of 13)
    Atopic Dermatitis (1 of 13) 1 Patient presents w/ skin manifestations suggestive of atopic dermatitis 2 DIAGNOSIS No ALTERNATIVE Do history & physical exam DIAGNOSIS confirm atopic dermatitis? Yes Patient suff ers from acute fl are-up Patient suff ers from disease of pruritus & inflammation persistence or frequent recurrences ACUTE FLAREUP TREATMENT MAINTENANCE TREATMENT A Non-pharmacological therapy A Non-pharmacological therapy • Patient/caregiver education • Same as acute fl are-up • Avoidance of trigger factors • Investigate precipitating factors of each fl are-up • Skin care • Phototherapy* - Bathing B Pharmacological therapy - Moisturizers/emollients Start at earliest sign of local recurrence: - Wet dressing • Calcineurin inhibitor (topical) B Pharmacological therapy or Any one of the following agents: Long-term: • Corticosteroid (topical) • Calcineurin inhibitor (topical), combined w/ • Calcineurin inhibitor (topical) • Corticosteroids (topical), intermittent use If skin infection is present: If skin infection is present: • Appropriate antibiotics, antifungals, • Antibiotics, antifungals, antivirals (oral &/or topical) antivirals (oral &/or topical) Symptomatic relief of pruritus: Symptomatic relief of pruritus: • Antihistamine (oral) • Antihistamine (oral) MIMS • • Continue Expert referral is recommended • non- Psychotherapeutic/ pharmacological psychopharmacological options therapy may be combined w/ the therapies EVALUATION listed below • Discontinue Yes No Disease A topical Non-pharmacological therapy remission (Severe • Continue therapy above corticosteroid &/ Refractory • Phototherapy or calcineurin Atopic B inhibitor Dermatitis) Pharmacological therapy • Potent corticosteroids (topical) © • Systemic corticosteroids • Systemic immunosuppressants *May be considered in patients >6 years of age w/ Scoring of Atopic Dermatitis (SCORAD) score of 25-50. Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS.
    [Show full text]
  • World Journal of Clinical Cases
    World Journal of W J C C Clinical Cases Submit a Manuscript: http://www.f6publishing.com World J Clin Cases 2018 November 26; 6(14): 854-861 DOI: 10.12998/wjcc.v6.i14.854 ISSN 2307-8960 (online) CASE REPORT Intralesional and topical glucocorticoids for pretibial myxedema: A case report and review of literature Fan Zhang, Xin-Yue Lin, Jian Chen, Shi-Qiao Peng, Zhong-Yan Shan, Wei-Ping Teng, Xiao-Hui Yu Fan Zhang, Xin-Yue Lin, Jian Chen, Shi-Qiao Peng, Zhong- Manuscript source: Unsolicited manuscript Yan Shan, Wei-Ping Teng, Xiao-Hui Yu, Department of Endocrinology and Metabolism, Institute of Endocrinology, Corresponding author to: Xiao-Hui Yu, MD, PhD, Professor, Liaoning Provincial Key Laboratory of Endocrine Diseases, The Department of Endocrinology and Metabolism, Institute of First Affiliated Hospital of China Medical University, Shenyang Endocrinology, Liaoning Provincial Key Laboratory of Endocrine 110001, Liaoning Province, China Diseases, The First Affiliated Hospital of China Medical Uni­ versity, No. 155, Nanjing North Street, Heping District, Shenyang ORCID number: Fan Zhang (0000­0002­0176­2715); Xin­Yue 110001, Liaoning Province, China. [email protected] Lin (0000­0002­8168­7531); Jian Chen (0000­0003­3589­7236); Telephone: +86­24­83283135 Shi­Qiao Peng (0000­0002­2164­2825); Zhong­Yan Shan (0000­0002­2849­2380); Wei­Ping Teng (0000­0002­6445­6192); Received: August 8, 2018 Xiao­Hui Yu (0000­0003­4802­9673). Peer-review started: August 9, 2018 First decision: August 24, 2018 Author contributions: All the authors materially participated
    [Show full text]
  • Evidence Review
    National Institute for Health and Care Excellence Draft for consultation Secondary bacterial infection of common skin conditions, including eczema: antimicrobial prescribing guideline Evidence review August 2020 Draft for consultation DRAFT FOR CONSULTATION Contents Disclaimer The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian. Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties. NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the Welsh Government, Scottish Government, and Northern Ireland Executive. All NICE guidance is subject to regular review and may be updated or withdrawn. Copyright © NICE 2020.
    [Show full text]
  • F Topical Steroid
    Topical Steroid 130 Clinical Practice Guideline for Topical Steroid Usage "#$%&'( )(*+,- ./$ 0'1,/' "#$%&'0*' 23+0($ "#$%&' 34 *, 3*/%2 1 "#$%&'"56 ,'7 8 )0*2 (, "#$%&'9":&" / -;< "#$%&' -&& 4*& -# '#= (Corticosteroid) !"#$ %&'()* + ,- ./ 0)1 '1 , 123 1 4& ()*','51(,6 7)) 9 />$ "'? / # !#817'12*%' %961 1 %9#23 ,' 1()*!#1% & 9:'%6 2;& , & 61!"# ( 1) 16&81'1= 131 8 )7 1 1(,6 1 , & 6 1-17 83403A)= 83403A)B , 83403 3# PsoriAsis(intertriginous) PsoriAsis PAlmoplAntAr psoriAsis Atopic dermAtitis (cHildren) Atopic dermAtitis (Adults) PsoriAsis of nAils SeborrHeic dermAtitis NummulAr eczemA DysHidrotic eczemA Intertrigo (non-infectious) Allergic contAct dermAtitis Lupus erytHemAtosus PrimAry irritAnt dermAtitis PempHigus PApulAr urticAriA LicHen plAnus PArApsoriAsis GrAnulomA AnnulAre LicHen simplex cHronicus Necrobiosis lipoidicA diAbeticorum SArcoidosis Insect bites %,- # &+ 9111./ 0U!&1)-6&5U5&1',2V99')6 '&'5&1 )+1!"#9 # 8&2V99' ' 6W2&5 1. 8-# '&5 1.1 5B44D3# (Form): ' %W2 #$ 46!&X+5&Y& (BAse) 8!# 1 2;&42(,,U (form) "& 6[ '&5 1.1.1 D)JKLJ (ointment) 18 : !"# )+,$ %&'8!#"-6"+5& * 8',$ %&' (# 9* W#$)!&$+ &$ %&' & (#( 1 &+ 91-^ ,' UU5$59* )+,$ %&'W# 98!# 4147W#1U5& ( 6$4#!"#9*4# 1 &% &*&* U5$5'1W6 1'& 1.1.2 1 )= (cream) : 2;&42(,, !"#W#1',$ %&'' %W2 * 8',$+ &$ %&''1 , "& :,X)'& ()*1 :,X)'& 9!"#1',$ %&', %^ ',"+5&()*71X', 6%&!a6'1 1'&,4 2;& 6%&$ 7 9 2;&2Va!&$4# (X#W# 132 1.1.3 2, -7(lotion) 0 ,N,# (solution) 9?, (gel) ,N 09B #$ (spray) : * 9*!"#1', , %^ U&()*$ 2* b&5,"& 6%&$ U()1c)18 ()* propylene glycol 7 98!# 1
    [Show full text]
  • Topical Halometasone Reduces Acute Adverse Effects Induced by Pulsed Dye Laser for Treatment of Port Wine Stain Birthmarks
    Journal of J Lasers Med Sci 2018 Winter;9(1):19-22 Original Article Lasers in Medical Sciences http://journals.sbmu.ac.ir/jlms doi 10.15171/jlms.2018.05 Topical Halometasone Reduces Acute Adverse Effects Induced by Pulsed Dye Laser for Treatment of Port Wine Stain Birthmarks Lin Gao†, Linhan Qian†, Li Wang, Kai Li, Rong Yin, Yanting Wang, Hanmei Kang, Wenting Song, Gang Wang* Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi’an, 710032, China † The first two authors contributed equally to the work. *Correspondence to Gang Wang, MD, PhD; Abstract Department of Dermatology, Introduction: Pulsed dye laser (PDL) for treatment of port wine stain (PWS) usually causes some Xijing Hospital, Fourth Military acute adverse effects, including pain, erythema, scabbing and swelling. This study aimed to Medical University, NO. 127 determine whether topical halometasone can be used to reduce these acute adverse effects for Changle West Rd., Xi’an, 710032, China. post-PDL care of patients. Tel/Fax: +86 2984775401; Methods: A total of 40 PWS subjects were enrolled in this study and randomly assigned into two Email: [email protected] regimens: PDL alone and PDL + halometasone. All subjects were given a single treatment of PDL with wavelength of 595 nm, fluence of 8.0~13.5 J/cm2, pulse duration of 0.45~20 ms (We mainly used purpuric pulse duration for PWS) and spot size of 7 mm. Subjects in the PDL + halometasone Published online 26 December group received topical application of halometasone daily for 3 days. Subjects were followed-up on 2017 days 3, 7 and one month post-PDL to evaluate the reduction of adverse effects.
    [Show full text]
  • Treatments for Atopic Eczema
    Health Technology Assessment 2000; Vol. 4: No. 37 Review Systematic review of treatments for atopic eczema C Hoare A Li Wan Po H Williams Health Technology Assessment NHS R&D HTA Programme HTA HTA How to obtain copies of this and other HTA Programme reports. An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (http://www.hta.ac.uk). A fully searchable CD-ROM is also available (see below). Printed copies of HTA monographs cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our Despatch Agents. Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph. You can order HTA monographs from our Despatch Agents: – fax (with credit card or official purchase order) – post (with credit card or official purchase order or cheque) – phone during office hours (credit card only). Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. Contact details are as follows: HTA Despatch Email: [email protected] c/o Direct Mail Works Ltd Tel: 02392 492 000 4 Oakwood Business Centre Fax: 02392 478 555 Downley, HAVANT PO9 2NP, UK Fax from outside the UK: +44 2392 478 555 NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30–40 titles).
    [Show full text]
  • WO 2017/207821 Al 07 December 2017 (07.12.2017) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/207821 Al 07 December 2017 (07.12.2017) W !P O PCT (51) International Patent Classification: A61K 45/06 (2006 .01) A61K 31/5578 (2006 .01) A61K 31/573 (2006.01) A61K 31/121 (2006.01) A61P 17/06 (2006.01) (21) International Application Number: PCT/EP2017/063629 (22) International Filing Date: 05 June 2017 (05.06.2017) (25) Filing Language: English (26) Publication Langi English (30) Priority Data: 1609719.8 03 June 2016 (03.06.2016) GB 1613 179.9 29 July 2016 (29.07.2016) GB 1704281 .3 17 March 2017 (17.03.2017) GB (71) Applicant: AVEXXIN AS [NO/NO]; Nordahl Bruns vei 2A, 7052 Trondheim (NO). (72) Inventors: JOHANSEN, Berit; Nordahl Bruns vei 2A, 7052 Trondheim (NO). FEUERHERM, Astrid Jullum- stro; Nordahl Bruns vei 2A, 7052 Trondheim (NO). (74) Agent: CAMPBELL, Neil; St Bride's House, 10 Salisbury Square, London Greater London EC4Y 8JD (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]